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Abstract
Background: Cystic echinococcosis (CE) is a chronic, complex and neglected zoonotic disease. CE occurs
worldwide. In humans, it may result in a wide spectrum of clinical manifestations, ranging from asymptomatic
infection to fatal disease. Clinical management procedures have evolved over decades without adequate
evaluation. Despite advances in surgical techniques and the use of chemotherapy, recurrence remains one of the
major problems in the management of hydatid disease. The aim of this study was to determine the frequency of
CE recurrence and the risk factors involved in recurrence.
Methods: A descriptive longitudinal-retrospective study was designed. We reviewed all patients diagnosed with CE
according to ICD-9 (code 122–0 to 122–9) criteria admitted at Complejo Asistencial Universitario de Salamanca,
Spain, between January 1998 and December 2015.
Results: Among the 217 patients studied, 25 (11.5%) had a hydatid recurrence after curative intention treatment.
Median duration of recurrence’s diagnosis was 12.35 years (SD: ±9.31). The likelihood of recurrence was higher
[OR = 2.7; 95% CI, 1.1–7.1; p < 0.05] when the cyst was located in organs other than liver and lung, 22.6% (7/31) vs
14.2% (31/217) in the cohort. We detected a chance of recurrence [OR = 2.3; 95% CI, 1.4–6.5; p > 0.05] that was two
times higher in those patients treated with a combination of antihelminthic treatments and surgical intervention
(20/141, 14.2%) than in patients treated with surgical intervention alone (5/76, 6.6%).
Conclusions: Despite advances in diagnosis and therapeutic techniques in hydatid disease, recurrence remains one of
the major problems in the management of hydatid disease. The current management and treatment of recurrences is
still largely based on expert opinion and moderate-to-poor quality of evidence. Consequently, large prospective and
multicenter studies will be needed to provide definitive recommendations for its clinical management.
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Background
Cystic echinococcosis (CE) is a chronic, complex and
neglected zoonotic disease caused by the larval stage (meta-
cestode) of Echinococcus granulosus. CE occurs worldwide
but is endemic to central Asia, northern and eastern Africa,
Australia, South America and the Mediterranean Basin
[1–3]. CE has peculiar features that imply difficulties in
the evaluation of its magnitude [2]. In humans, it may re-
sult in a wide spectrum of clinical manifestations, ranging
from asymptomatic infection to fatal disease [4]. Its clin-
ical management is complex, has evolved over decades
without adequate evaluation of efficacy, effectiveness, rate
of adverse reactions, relapse rate, and cost. The current
management and treatment of CE is still largely based on
expert opinion and moderate-to-poor quality of evidence
[5, 6]. Despite advances in surgical techniques and the
use of chemotherapy, recurrence remains one of the major
problems in the management of hydatid disease [7].
Overall, CE recurrence rates appear to be highly variable
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(0%–22%) and are seen in intervals ranging from 3 months
to 20 years from the first operation [8]. The recurrence of
disease may present with major complications including
pyogenic infection, intrabiliary rupture, or anaphylaxis.
However, it is usually initially asymptomatic, and therefore
regular long-term follow-up should be routine after pri-
mary treatment [9, 10]. Recurrent disease is the main cri-
teria of failure of treatment [10]. Finally, the absence of
protocols and clinical guidelines of the “best” management
for echinococcal cysts is also a clear factor underlying recur-
rent CE [11]. The purpose of this study was to determine
the frequency of CE recurrence, the clinical setting and the
risk factors involved in recurrence. Moreover, we studied
the treatment applied to these patients and their mortality.
Methods
The design was a descriptive longitudinal-retrospective
study. We reviewed all patients diagnosed with CE ac-
cording to ICD-9 (code 122–0 to 122–9) criteria admit-
ted at Complejo Asistencial Universitario de Salamanca
(CAUSA) between January 1998 and December 2015.
CAUSA is a tertiary care hospital, located in western
Spain. It covers an area of 12,350 km2 with a population
of approximately 350,500 individuals [12]. The clinical
and epidemiological data were collected after revision of
medical records. Diagnosis and classification of CE were
assessed according to the criteria proposed by the World
Health Organization Informal Working Group on
Echinococcosis for CE [6]. Recurrent disease was defined
as the appearance of new active cysts after intentional
curative therapy, including the reappearance with con-
tinuous growth of live cysts at a site of a previously
treated cyst or the appearance of new distant disease. To
be included in the study, at least one of the following
radiological images of the hydatidosis-affected area was
to be performed: i) abdominal ultrasonography (US)
and/or ii) computed tomography (CT) in the twelve
postoperative months. During follow-up, cysts areas im-
aged by US and/or CT without a change in size and
without evidence of daughter cysts were not considered
as recurrence. Patients without follow-up or radiological
image, with missing data and who were not recipients of
surgery were excluded from the study.
Subsequently, a search was conducted in PubMed
from 1966 to January 2016 with relapses, recurrences,
hydatidosis and Echinococcus granulosus terminus. Clin-
ical cases and non-relevant works were discarded.
The statistical analysis
The results were expressed as percentages for categorical
variables and as the mean and standard deviation (SD)
for continuous variables. A chi-square test was used to
compare the association between categorical variables,
such as clinical and demographics variables, and the
measured outcome was expressed as the odds ratio (OR)
together with the 95% CI for OR. Continuous variables
were compared with Student’s t-test, ANOVA or the
Mann–Whitney U test for two groups, depending on
their normal or non-normal distribution. Additionally,
we applied the corresponding regression models for
multivariate analysis. Recurrence rates were analyzed by
Kaplan–Meier method for patients undergoing surgery
and apparently disease-free at discharge from hospital.
We considered a statistically significant difference from
chance at a p-value <0.05. All data were analyzed with
SPSS 23 (Statistical Package for the Social Sciences).
Results
A total of 571 patients were diagnosed with CE accord-
ing to ICD-9 (code 122–0 to 122–9) criteria in CAUSA
between January 1998 and December 2015. Of these,
343 (60.0%) patients were treated with curative intention
(surgery & PAIR [Puncture, Aspiration, Injection, and
Re-aspiration]). After exclusion criteria, the study sample
was 217 patients. The main epidemiological and clinical
data of these patients were shown in Table 1. The mean
(±SD) of follow-up was 3.42 ± 3.50 years. The median
(25th and 75th percentiles) value was 2.17 years (0.96
and 4.46, respectively). Among the 217 patients, a total
of 423 cysts were detected and the cysts per patient
mean (±SD) was 1.95 ± 2.66.
A total of 25 (11.5%) patients had CE recurrences dur-
ing their follow-up. The mean time until diagnosis of CE
recurrence was 12.35 years ±9.31 (interval range: 0.02–
41.61 years). Four cases were detected in the five first
years after surgical intervention, 7 cases between 5 and
10 years of surgical intervention, and 14 cases after
10 years of surgical intervention (Fig. 1). The time trend
of recurrences are shown in Fig. 2. In 23 (92%) cases, re-
currence appeared next to the surgical site, and only two
(8%) recurrences appeared remote to the surgical site
(one patient had recurrent CE in the psoas muscle and
other in lumbar paravertebral musculature).
Among patients with recurrent CE, 16 (64.0%) were
asymptomatic at the moment of diagnosis, with it usu-
ally an incidental diagnosis. Nine (36.0%) recurrent cases
had clinical manifestations of complicated CE: 6 cases
had mechanical complications; two cases had structural
displacements; one case had vomica (caused by bron-
chial fistula); one case had thoracic pain (associated to
bronchial fistula); one case was jaundice (by biliary fis-
tula) and one case presented with sciatica (caused by
spinal CE). Two patients with recurrent CE presented
secondary super-infections pyogenic with suppurative
cholangitis and two cases presented urticarial reactions.
No patient with recurrent CE died as a consequence of
recurrent complicated cyst. The variables associated with
recurrence are shown in Table 2. We did not detect any
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epidemiological variables associated with the occurrence
of relapses in patients (p > 0.05).
In regard to the location of primary CE, recurrence
was higher in primary CE located in organs other than
the liver or lung [22.6% vs 9.8% vs 0% (OR 2.7 (1.1–7.1)
vs 0.3 (0.1–0.9), p < 0.05]. Recurrence was higher in pa-
tients surgical treated with two or more vs one cyst
[13.8% vs 10.2%, OR 1.4 (0.6–3.2)], although these re-
sults were not significant (p > 0.05) Recurrences were
more frequent in primary cysts larger than 7 cm that in
smaller cysts, but these differences were not significant
[13.1% vs 9.4%, OR 1.4 (95% CI 0.6–3.4), p > 0.05]. With
respect to WHO classification, relapses were more fre-
quently detected between CE2-CE3 than CE4-CE5 [12/
91 (13.2%) vs (7,6%); OR 1.6 (95% CI 0.6–4.3) p > 0.05],
but these differences were not significant.
We detected the likelihood of recurrence was twice as
likely in those patients treated with a combination of
anti-helminthic treatments and surgical intervention
than patients treated with surgical intervention alone
[14.2% vs 6.6%, OR 2.34 (CI 95 0.84–6.52) p > 0.05)].
The logistic regression model shows the following clin-
ical pattern: patients with hepatic cysts are treated with
surgery alone [Exp (B) = 3.50; 95% CI, 1.20–10.18;
p < 0.05], whereas patients with localized cysts in organs
other than liver or lung receiving combination therapy
[Exp (B) = 2.72; 95% CI, 1.03–7.19; p < 0.05].
Finally, we evaluated the treatment given to patients
with recurrences (Tables 1 and 2). All patients (25,
100%) with recurrences, were treated: 5 (10%) patients
with surgical treatment alone, and 20 (80%) patients
with a combination of surgical and anti-helminthic treat-
ments (50% with albendazole and 50% albendazole and
praziquantel). The mortality in both groups was null.
Discussion
Cyst echinococcosis (CE) is a parasitic disease highly
complex, due mainly to involvement of different organs
and tissues and its very slow course (usually over de-
cades). During this large time period, CE may pass from
stages active to inactive, and its clinical setting may
range from an asymptomatic form to several complica-
tions, including fatal disease [4].
The lack of large, longitudinal and controlled studies
is due to different factors. First, the chronicity of the dis-
ease requires a follow-up of several years to evaluate re-
lapse rates. Second, because there are not tools sensitive
enough to allow us to arrive at early diagnosis, and con-
sequently, optimal monitoring after treatment. Finally,
its status as a neglected disease contributes to scarce
funding for investigations of CE [6]. As a consequence,
clinical management has evolved over decades based
only on poor-to-moderate quality of evidence and rec-
ommendation strengths [6, 7]. Accordingly, major con-
straints of our work are conditioned by retrospective
design. Therefore, the “best” management for CE is still
a subject of debate [7]. Besides, in the WHO-IWGE Ex-
pert Consensus (World Health Organization-Informal
Working Group on Echinococcosis) there is no clear
definition of relapse, recurrence and reinfection, which
reflects difficulties found in clinical practice.
However, factors such as the introduction of the
WHO-IWGE classification for CE or the recent
European project HERACLES, have allowed the estab-
lishment of a framework that may contribute to ad-
vances in the treatment of CE [13].
Table 1 Main epidemiological and clinical data in 217 patients
included in the study
Patients n/N (%)
Age, mean ± SD (range),years
≤ 59 years
52.55 ± 18.20 (5–82)
124/217 (57.1)
Male sex 133/217 (61.3)
Patients from rural areas 148/217 (68.2)
Professional activity-agriculture/livestock 31/217 (14.3)
Contact with animals 60/217 (27.6)
Immigrants 6/217 (2.8)
Comorbidity 73/217 (33.6)









Eosinophilia (>0.450 × 109 eosinophils/L) 65/217 (29.9)
ELISA (>1/80) 105/217 (48.4)







No. of cysts, mean ± SD (range)
1
≥ 2
1.95 ± 2.66 (1–20)
137/217 (63.1)
80/217 (36.9)
Size of the largest cyst, mean ± SD (range),cm
≥ 7 cm
≤ 6.9 cm






















Cohort mortality from all causes 13/217 (6.0)a
Mortality attributable to hydatidosis 2/217 (0.9)b
aExitus ethiology: cardiovascular 1. Cancer 1. Infectious 5. No data 6
bExitus ethiology for E. granulosus: Infectious (sepsis) 1. Hemoptysis 1
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Today, standard of treatment in CE is based in the use
of different surgical techniques with or without chemo-
therapy and recurrence remains one of the major prob-
lems in the management of CE [14] as it can occur with
any of the therapeutic methods employed [14]. Although,
there are many series of patients with CE, only a few stud-
ies specifically analyzed the presence of recurrences and
assessed its frequency and surrounding circumstances
(Table 3) [8, 14–21].
The aim of this work was to determine, in our center,
the frequency of recurrence after CE surgery, and the
main factors associated with this recurrence. Our work
analyzed recurrence using data from clinical records.
Therefore, we detected a rate of recurrence above 11%.
Fig. 1 Kaplan-Meier Curve of recurrence-free time in the cohort
Fig. 2 Number of recurrences during follow-up time
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The rate of recurrence showed by other groups ranged
from 0% to 22% in post-surgery [8, 9, 11, 19, 21] and
0%–1.27% in other percutaneous treatments [22]. This
wide range reflects several methods employed in these
studies, especially with regards to methods used and
duration in the follow-up. Despite this, it is probable
that all these data on recurrence, including the highest,
undervalue the actual incidence.
In regard to the methods used, serological methods
did not allow us an optimal follow-up because antibody
titers may persist for years after the removal of a cyst.
Consequently the relapse must be confirmed by ultra-
sonography or CT [19]. The differentiation of remaining
cavities of effectively treated cysts from locally recurrent
disease is difficult, therefore we relied on the accepted
imaging marker of the increase in size of the cyst on ser-
ial examination, which proved to be effective [19].
Recurrence of CE may be diagnosed after 3 months to
20 years post-surgery, with the mean time ranging 2 and
10 years [9, 10, 17, 18]. In our work, the mean time to
detection was lengthy. This is possible because a follow-
up prospective after surgery of patients with CE has not
been well standardized in our hospital. Therefore, most
patients were only prospectively followed-up for one or
two years.
In regard to our clinical setting, more than half of our
patients were asymptomatic at the moment of diagnosis
of relapse. Nevertheless, we also detect patients with CE
complications, including pyogenic super-infection, bil-
iary and pleural fistula, or immunological reactions such
as a type of urticarial rash. However, there is to highlight
that no patient with recurrent CE died as result of these
complications. These results are similar to those reported
by other authors (Table 3). Consequently, it has been sug-
gested that the postoperative follow-up period should not
be shorter than 3 years and should be continued for as
long as possible, due the frequently asymptomatic recur-
rence and the onset of symptoms 3–4 years after surgery
[7, 19]. Our results support this strategy, although the effi-
ciency of a screening program in relation to risk and cost
has not been established.
Recurrence usually occurs in the same area of the pri-
mary CE. Accordingly, in this paper, we detected a local
recurrence in more than 90% of cases, and in only two
Table 2 Study of factors associated with recurrence. Bi-variable analyses between host factors, primary cyst and treatment used with
recurrence
Patients with recurrences n/N (%) OR (IC95%) p-value*
Host factors
Age ≤ 59 years 17/124 (13.7) 1.6 (0.6–4.0) 0.244
Male sex 18/133 (13.5) 1.7 (0.6–4.3) 0.243
Patients from rural areas 17/148 (11.5) 0.9 (0.4–2.4) 0.982
Professional activity-agriculture/livestock 2/31 (6.5) 0.4 (0.1–2.1) 0.340
Contact with animals 4/60 (6.7) 0.4 (0.1–1.4) 0.166
Immigrants 0/6 (0.0) – –
Comorbidity 7/73 (9.6) 0.7 (0.2–1.8-) 0.526
Cyst primary factors
Complicated 9/88 (10.2) 0.8 (0.3–1.9) 0.622




























Factors associated to treatment
Combinated treatment (Antihelminths & surgical) 20/141 (14.2) 2.3 (1.4–6.5) 0.094
Surgical technics 5/76 (6.6)
Surgical treatment complications 7/38 (18.4) 2.0 (0.7–5.2) 0.142
*p-value of the test: Total patients with treatment with curative intention-follow-up & Recurrences. Statistical significance level of 5% (p < 0.05)
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cases was recurrence detected to distance. This fact
could be due to the dissemination of the protoscolex
from viable CE during surgical procedure by contamin-
ation of the surgical bed. However, it is also possible that
the dissemination occurs before surgery, especially in
complicated CE.
The other objective of our work was to find risk fac-
tors associated with recurrence, to implement measure
to decrease its risk. In the literature, numerous risk
factors have been described, although with important
differences between studies [19]. Regarding the factors
associated with the host, in our work we found that
the epidemiological variables were not associated with
recurrences including professional activity–agriculture/
livestock or contact with animals. This supports the fact
that recurrences are more frequently caused by dissemin-
ation before or during surgical procedure than subsequent
reinfections.
With respect to primary CE, some characteristics were
associated with recurrence. In our study, the location of
CE outside of the liver and lung, followed by location in
the liver were associated with higher recurrence. Never-
theless, in other series location in the liver [14, 15], in
the difficult surgical access [16] or multiple abdominal
cysts [14, 15], were variables associated to relapse. Other
factors affecting the cyst such as its size, especially in
cases larger than 7–10 cm [14, 11] or stages I-II WHO
[11] have been associated with recurrence. In our study,
we found more frequent relapses in these groups of
patients, although these differences were not statistically
significant.
In regard to surgery techniques used, the rate of recur-
rences was higher with laparoscopic surgery, than with
open conservative interventions (8.89% vs 3.15%) [16].
Other variables associated with a higher risk or recur-
rences included: leaving viable material behind during
conservative operative interventions [16], incomplete ex-
cision of the endocyst, missing the cysts pre- or intraop-
eratively and incomplete pericystectomy [19] spillage
during surgical removal [15, 17, 18, 23]. However, there
are no reports showing the association of recurrence
and the choice of incision [16]. Two important factors
are the surgeon’s practice and experience [15, 24].
In our series, all patients were subjected to open surgery
and we do not detect factors increasing the risk of relapse.
Finally, anthelminthic drugs as albendazole or mebenda-
zole, with or without praziquantel, have been used for de-
crease the risk of relapse in patients undergoing surgery
for CE. The results in animal models and humans have
shown a reduced recurrence in patients operated with
these drugs prophylactically. According to a recommenda-
tion of the WHO Informal Working Group on Echinococ-
cosis and other studies, antiparasitic chemotherapy is
considered today an indication to prevent secondary
echinococcosis and reduce the risk of recurrence [14]. In
our work, we detected a higher rate of relapse in patients
with combined treatment than with surgery alone.
This was possibly a selection bias due to the higher use of
combined treatment in complicated cyst CE or greater
surgical difficulty.
With respect to the treatment of recurrence, there is
no consensus in the literature. Not every patient with
documented recurrent active hydatid disease needs to be
treated with surgical treatment due to the fact that hydatid
disease progresses slowly. Therefore, local recurrence,
small cysts in asymptomatic patients with advanced age
and/or serious co-morbid conditions are best followed
and treated only when complications develop [17, 25].
Haddad et al. suggested that in patients with recurrences
smaller than 5 cm in diameter, antihelminthic therapy for
3–6 months was the ideal treatment, and the cysts with
difficult location for surgery should be drained percutan-
eously. In the other hand, there are also reports suggesting
that in patients, for whom albendazole treatment for
the primary disease failed, treatment of recurrence
would also fail. Treatment options for local recur-
rence are similar to those for the primary disease.
However, radical interventions are also suggested in
patients with recurrence who previously underwent
surgery conservatively. Nevertheless, these radical op-
erations are technically more difficult, and reopera-
tions have higher morbidity and mortality rates [14,
16]. Therefore, the choice between conservative vs
radical interventions depends on a number of factors,
such as location, size and stage of the cysts/lesions,
and availability of therapeutic options in each health
center. In our work, all patients with recurrent CE
were subjected to surgical intervention and the mor-
tality was null, including complicated CE cases. This
supports the notion that surgical treatment in well se-
lected cases is associated with good outcomes.
Conclusions
CE recurrence remains one of the major problems in the
management of hydatid disease. It can occur decades
after surgery, and in the clinical setting is usually diag-
nosed only incidentally. However, primary cyst can be
detected as a complicated cyst. The main risk factor as-
sociated with relapse is the location of the primary cyst
outside of the liver and lung followed by liver cysts.
Mortality in this group of patients was null and surgical
intervention of recurrent cyst in well-selected cases is
associated with good outcomes.
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